Elucidation of disease mechanisms underlying rheumatic immune-related adverse events may lead to novel therapeutic strategies for autoimmune diseases
- PMID: 32769155
- DOI: 10.1136/annrheumdis-2020-217995
Elucidation of disease mechanisms underlying rheumatic immune-related adverse events may lead to novel therapeutic strategies for autoimmune diseases
Keywords: autoimmune diseases; giant cell arteritis; immune system diseases.
Conflict of interest statement
Competing interests: MH received research grants and/or speaker fees from Brystol-Meyers, Eisai, Eli Lilly and Tanabe-Mitsubishi. Department of Advanced Medicine for Rheumatic Diseases is supported by five pharmaceutical companies (Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd, UCB Japan Co. Ltd, AYUMI Pharmaceutical Co. and Asahi Kasei Pharma Co.). These companies did not participate in the writing of the manuscript or decision to submit the manuscript for the publication.
Comment on
-
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.Ann Rheum Dis. 2021 Jan;80(1):36-48. doi: 10.1136/annrheumdis-2020-217139. Epub 2020 Apr 23. Ann Rheum Dis. 2021. PMID: 32327425 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical